Focus on Lipids Care

Back to articles

Anacetrapib safely lowers LDL and raises HDL cholesterol

KEY POINT

According to results from the DEFINE (Determining the Efficacy and Tolerability of Cholesteryl Ester Transfer Protein [CETP] Inhibition with Anacetrapib) trial, presented as a late-breaking clinical trial at the American Heart Association’s Scientific Sessions 2010 and published in the New England Journal of Medicine, anacetrapib (Merck) increased HDL cholesterol levels and decreased LDL cholesterol levels in patients with dyslipidemia without serious adverse effects.

SOURCES

Cannon CP et al. Primary results of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapib. Circulation. 2010;122:2215–26.

Cannon CP. Primary results of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapib. Late-breaking papers. Presented at the 2010 Scientific Sessions of the American Heart Association;  Chicago: 17 Nov 2010.

Cannon CP et al. http://www.nejm.org/doi/full/10.1056/NEJMoa1009744http://www.nejm.org/doi/full/10.1056/NEJMoa1009744 N Engl J Med. 2010;363:2406–15.